In HFD-induced obese mice, resveratrol (RSV) supplementation reduced body weight gain, improved glucose tolerance, corrected lipid profiles, and suppressed adipose tissue inflammation. Mechanistically, RSV upregulated β3-adrenergic receptor (β3-AR), phosphorylated AMPKα, and uncoupling protein 1 (UCP1) — a triad collectively driving lipolysis, fatty acid oxidation, and adaptive thermogenesis in adipose tissue. The findings emerged from a combined network pharmacology screen and in vivo mouse model.
Resveratrol's metabolic promise has been debated for over two decades, with early excitement tempered by poor bioavailability and inconsistent human trial results. This study adds mechanistic granularity by pinpointing the β3-AR/AMPKα/UCP1 thermogenic axis — a pathway that converts white adipose tissue toward a metabolically active beige phenotype — as a plausible target. This is conceptually significant: β3-AR agonism is an active pharmaceutical target for obesity, and demonstrating that a food-derived polyphenol can engage this receptor adds translational interest.
However, the limitations are substantial. This is an animal-only study, and RSV's notoriously low oral bioavailability in humans makes direct extrapolation premature. Network pharmacology, while hypothesis-generating, is in silico and not causal. The abstract reports no specific dosages, making human-equivalent calculations impossible. Overall, this is confirmatory and mechanistically incremental — useful for researchers but insufficient to change dietary recommendations for adults managing weight.
